Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever

Observational Study on the Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever

The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue. The main questions it aims to answer are: 1 What are the key abnormal items in blood routine indicators of dengue patients? 2 Does dengue affect liver function in patients? Will there be liver damage? And when? 3. What are the specific clinical manifestations of dengue patients?

Study Overview

• Status: Completed
• Conditions: Dengue Fever
• Intervention / Treatment: Other: Observational studies did not involve any interventions

• Study Type: Observational
• Enrollment (Actual): 500

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Foshan, Guangdong, China, 528000
      • Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Foshan, 528051, Guangdong, China.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The subjects in this study were dengue fever patients.

Description

• Inclusion Criteria**:

  • Meet the clinical diagnostic criteria for dengue fever, with blood indicators showing that the dengue antigen is positive.
  • No age limit for inclusion.
  • Voluntarily agree to participate in the study and sign the informed consent.
  • Complete clinical data available, including symptoms and laboratory tests, to support subsequent analysis.

• Exclusion Criteria**:

  • Incomplete or unavailable clinical data. Patients will be excluded if sufficient laboratory data and symptoms cannot be collected.
  • Unable to understand or unwilling to sign the informed consent for any reason.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
WBC	WBC (White Blood Cell count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
HGB (Hemoglobin)	HGB (Hemoglobin), unit: g/dL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
PLT (Platelet count)	PLT (Platelet count), unit: cells/µL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024
ANC (Absolute Neutrophil Count)	ANC (Absolute Neutrophil Count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.	From January 2024 to December 2024

Collaborators and Investigators

• Sponsor: Foshan Hospital of Traditional Chinese Medicine

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2024
• Primary Completion (Actual): December 1, 2024
• Study Completion (Actual): December 1, 2024

Study Registration Dates

• First Submitted: February 27, 2025
• First Submitted That Met QC Criteria: March 13, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: March 13, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vector Borne Diseases; Mosquito-Borne Diseases; Infections; RNA Virus Infections; Virus Diseases; Arbovirus Infections; Flavivirus Infections; Flaviviridae Infections; Hemorrhagic Fevers, Viral; Body Temperature Changes; Dengue; Fever
• Other Study ID Numbers: Foshan Hospital of Traditional

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No